Risk factors for loss of residual renal function in children treated with chronic peritoneal dialysis

Kidney International

Volumn 88, Issue 3, 2015, Pages 605-613

  Ha, Il Soo ^a   Yap, Hui K ^b   Munarriz, Reyner L ^c   Zambrano, Pedro H ^d   Flynn, Joseph T ^e   Bilge, Ilmay ^f   Szczepanska, Maria ^g   Lai, Wai Ming ^h   Antonio, Zenaida L ⁱ   Gulati, Ashima ^j   Hooman, Nakysa ^k   Van Hoeck, Koen ^l   Higuita, Lina M S ^m   Verrina, Enrico ⁿ   Klaus, Günter ^o   Fischbach, Michel ^p   Riyami, Mohammed A ^q   Sahpazova, Emilja ^r   Sander, Anja ^s   Warady, Bradley A ^t   Schaefer, Franz ^u   more..

^a Seoul National University Children's Hospital   (South Korea)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^c HOSPITAL NACIONAL CAYETANO HEREDIA   (Peru)

^d Pediatra Reumatólogo Unidad Inmuno Reumatología Hospital Dr Exequiel González Cortés   (Chile)

^e SEATTLE CHILDREN S HOSPITAL   (United States)

^f ISTANBUL UNIVERSITY   (Turkey)

^g Regional Hospital in Zabrze   (Poland)

^h Princess Margaret ^*  (Hong Kong)

ⁱ National Kidney and Transplant Institute Philippines   (Philippines)

^j ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^k IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^l ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^m Baxter Servicio al Cliente Colombia   (Colombia)

ⁿ G GASLINI INSTITUTE   (Italy)

^o KfH Pediatric Kidney Center   (Germany)

^p HÔPITAL DE HAUTEPIERRE   (France)

^q ROYAL HOSPITAL   (Oman)

^r Nephrology Unit   (Macedonia)

^s UNIVERSITY OF HEIDELBERG   (Germany)

^t CHILDREN S MERCY HOSPITAL   (United States)

^u UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

more..

Author keywords

children; oligoanuria; peritoneal dialysis; registry; risk factors; urine volume

Indexed keywords

ICODEXTRIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIALYSIS FLUID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ARTICLE; ASIA; CHILD; CONTROLLED STUDY; DIURESIS; DRUG USE; FEMALE; FOLLOW UP; GLOMERULOPATHY; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NORTH AMERICA; OLIGURIA; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESIDUAL URINE; RISK FACTOR; RISK REDUCTION; SURVIVAL TIME; ULTRAFILTRATION; URINE VOLUME; ADVERSE EFFECTS; AGE; CLINICAL TRIAL; DRUG EFFECTS; EUROPE; KIDNEY; KIDNEY DISEASES; KIDNEY FUNCTION TEST; MULTICENTER STUDY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; REGISTER; TIME FACTOR; TREATMENT OUTCOME;

AGE FACTORS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASIA; CHILD; DIALYSIS SOLUTIONS; DIURESIS; DIURETICS; EUROPE; FEMALE; HUMANS; KIDNEY; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; MALE; NORTH AMERICA; OLIGURIA; PERITONEAL DIALYSIS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84940796901     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2015.108     Document Type: Article

References (42)

1. Wang AY, Lai KN. The importance of residual renal function in dialysis patients. Kidney Int. 2006; 69: 1726-1732.
2. Marron B, Remon C, Perez-Fontan M, et al. Benefits of preserving residual renal function in peritoneal dialysis. Kidney Int. 2008; 73: S42-S51.
3. Perl J, Bargman JM. The importance of residual kidney function for patients on dialysis: a critical review. Am J Kidney Dis. 2009; 53: 1068-1081.
4. Moist LM, Port FK, Orzol SM, et al. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol. 2000; 11: 556-564.
5. Hidaka H, Nakao T. Preservation of residual renal function and factors affecting its decline in patients on peritoneal dialysis. Nephrology. 2003; 8: 184-191.
6. Caravaca F, Dominguez C, Arrobas M. Predictors of loss of residual renal function in peritoneal dialysis patients. Perit Dial Int. 2002; 22: 414-417.
7. Bernardo A, Fonseca I, Rodrigues A, et al. Predictors of residual renal function loss in peritoneal dialysis: is previous renal transplantation a risk factor?. Adv Perit Dial. 2009; 25: 110-114.
8. Johnson DW, Mudge DW, Sturtevant JM, et al. Predictors of decline of residual renal function in new peritoneal dialysis patients. Perit Dial Int. 2003; 23: 276-283.
9. Feber J, Scharer K, Schaefer F, et al. Residual renal function in children on haemodialysis and peritoneal dialysis therapy. Pediatr Nephrol. 1994; 8: 579-583.
10. Michels WM, Verduijn M, Grootendorst DC, et al. Decline in residual renal function in automated compared with continuous ambulatory peritoneal dialysis. Clin J Am Soc Nephrol. 2011; 6: 537-542.
11. Hufnagel G, Michel C, Queffeulou G, et al. The influence of automated peritoneal dialysis on the decrease in residual renal function. Nephrol Dial Transplant. 1999; 14: 1224-1228.
12. Hiroshige K, Yuu K, Soejima M, et al. Rapid decline of residual renal function in patients on automated peritoneal dialysis. Perit Dial Int. 1996; 16: 307-315.
13. Singhal MK, Bhaskaran S, Vidgen E, et al. Rate of decline of residual renal function in patients on continuous peritoneal dialysis and factors affecting it. Perit Dial Int. 2000; 20: 429-438.
14. Liao CT, Chen YM, Shiao CC, et al. Rate of decline of residual renal function is associated with all-cause mortality and technique failure in patients on long-Term peritoneal dialysis. Nephrol Dial Transplant. 2009; 24: 2909-2914.
15. Drechsler C, de Mutsert R, Grootendorst DC, et al. Association of body mass index with decline in residual kidney function after initiation of dialysis. Am J Kidney Dis. 2009; 53: 1014-1023.
16. Bragg-Gresham JL, Fissell RB, Mason NA, et al. Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS). Am J Kidney Dis. 2007; 49: 426-431.
17. Herget-Rosenthal S, von Ostrowski M, Kribben A. Definition and risk factors of rapidly declining residual renal function in peritoneal dialysis: an observational study. Kidney Blood Press Res. 2012; 35: 233-241.
18. Shin SK, Noh H, Kang SW, et al. Risk factors influencing the decline of residual renal function in continuous ambulatory peritoneal dialysis patients. Perit Dial Int. 1999; 19: 138-142.
19. Coronel F, Perez-Flores I, Calvo N, et al. Impact of cardiovascular events on residual renal function during the first year of peritoneal dialysis. Perit Dial. 2007; 27: 454-456.
20. Cho Y, Johnson DW, Badve SV, et al. The impact of neutral-pH peritoneal dialysates with reduced glucose degradation products on clinical outcomes in peritoneal dialysis patients. Kidney Int. 2013; 84: 969-979.
21. Shemin D, Bostom AG, Lambert C, et al. Residual renal function in a large cohort of peritoneal dialysis patients: change over time, impact on mortality and nutrition. Perit Dial Int. 2000; 20: 439-444.
22. Chadha V, Blowey DL, Warady BA. Is growth a valid outcome measure of dialysis clearance in children undergoing peritoneal dialysis?. Perit Dial Int. 2001; 21: S179-S184.
23. Bakkaloglu SA, Saygili A, Sever L, et al. Assessment of cardiovascular risk in paediatric peritoneal dialysis patients: a Turkish Pediatric Peritoneal Dialysis Study Group (TUPEPD) report. Nephrol Dial Transplant. 2009; 24: 3525-3532.
24. Guzzo I, Mancini E, Wafo SK, et al. Residual renal function and nutrition in young patients on chronic hemodialysis. Pediatr Nephrol. 2009; 24: 1391-1397.
25. Lang SM, Bergner A, Topfer M, et al. Preservation of residual renal function in dialysis patients: effects of dialysis-Technique-related factors. Perit Dial Int. 2001; 21: 52-57.
26. Misra M, Vonesh E, Van Stone JC, et al. Effect of cause and time of dropout on the residual GFR: a comparative analysis of the decline of GFR on dialysis. Kidney Int. 2001; 59: 754-763.
27. Lysaght MJ, Vonesh EF, Gotch F, et al. The influence of dialysis treatment modality on the decline of remaining renal function. ASAIO Trans. 1991; 37: 598-604.
28. Borzych-Duzalka D, Bilginer Y, Ha IS, et al. Management of anemia in children receiving chronic peritoneal dialysis. J Am Soc Nephrol. 2013; 24: 665-676.
29. Medcalf JF, Harris KP, Walls J. Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis. Kidney Int. 2001; 59: 1128-1133.
30. Liao CT, Shiao CC, Huang JW, et al. Predictors of faster decline of residual renal function in Taiwanese peritoneal dialysis patients. Perit Dial Int. 2008; 28(Suppl 3): S191-S195.
31. van Olden RW, van Meyel JJ, Gerlag PG. Acute and long-Term effects of therapy with high-dose furosemide in chronic hemodialysis patients. Am J Nephrol. 1992; 12: 351-356.
32. Takatori Y, Akagi S, Sugiyama H, et al. Icodextrin increases technique survival rate in peritoneal dialysis patients with diabetic nephropathy by improving body fluid management: a randomized controlled trial. Clin J Am Soc Nephrol. 2011; 6: 1337-1344.
33. Cho Y, Johnson DW, Craig JC, et al. Biocompatible dialysis fluids for peritoneal dialysis. Cochrane Database Syst Rev. 2014; 3: CD007554.
34. Johnson DW, Brown FG, Clarke M, et al. Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes. J Am Soc Nephrol. 2012; 23: 1097-1107.
35. Lui SL, Yung S, Yim A, et al. A combination of biocompatible peritoneal dialysis solutions and residual renal function, peritoneal transport, and inflammation markers: a randomized clinical trial. Am J Kidney Dis. 2012; 60: 966-975.
36. Fan SL, Pile T, Punzalan S, et al. Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function. Kidney Int. 2008; 73: 200-206.
37. Kim S, Oh J, Kim S, et al. Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study. Nephrol Dial Transplant. 2009; 24: 2899-2908.
38. Haag-Weber M, Kramer R, Haake R, et al. Low-GDP fluid (Gambrosol trio) attenuates decline of residual renal function in PD patients: a prospective randomized study. Nephrol Dial Transplant. 2010; 25: 2288-2296.
39. Wuhl E, Trivelli A, Picca S, et al. Strict blood-pressure control and progression of renal failure in children. N Engl J Med. 2009; 361: 1639-1650.
40. Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensinconverting enzyme inhibition: a patient-level meta-Analysis. Ann Intern Med. 2003; 139: 244-252.
41. Harambat J, van Stralen KJ, Schaefer F, et al. Disparities in policies, practices and rates of pediatric kidney transplantation in Europe. Am J Transplant. 2013; 13: 2066-2074.
42. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004; 114: 555-576.